Search results
Results From The WOW.Com Content Network
Genentech was founded by venture capitalist Robert A. Swanson and biochemist Dr. Herbert W. Boyer. After a meeting in 1976, the two decided to start a biotechnology company, Genentech. Although the two confidently assert that it was the first biotech company, others clearly came before, including Cetus Corporation which was founded in 1971.
June 30, 2023 at 9:04 AM. (Reuters) - Genentech will withdraw Gavreto from use in the United States for treating a type of thyroid cancer as it was not feasible for the Roche unit to pursue the ...
October 23, 2023 at 3:27 PM. By Blake Brittain. (Reuters) - Swiss pharmaceutical company Roche has settled a patent lawsuit against U.S. biotech firm Biogen over its biosimilar version of Roche's ...
On 22 January 2008, Roche acquired Ventana Medical Systems for $3.4 billion. [22] On 2 January 2009, Roche acquired Memory Pharmaceuticals Corp. [23] On 26 March 2009, Roche acquired Genentech for $46.8 billion. [24]
Aviv Regev (born 11 July 1971) [3] is a computational biologist and systems biologist and Executive Vice President and Head of Genentech Research and Early Development in Genentech/Roche. [4] She is a core member (on leave) at the Broad Institute of MIT and Harvard and professor (on leave) at the Department of Biology of the Massachusetts ...
Roche will finally buy Genentech (DNA) after months of fighting over a price for the acquisition. According to The Wall Street Journal (subscription required), "Swiss drug maker Roche Holding AG ...
Emactuzumab was originally developed by Roche/Genentech. In August 2020, Celleron Therapeutics signed a deal to acquire an exclusive worldwide license for the asset. In November 2020, Celleron Therapeutics incorporated a subsidiary, SynOx Therapeutics, to focus on the development, registration, and commercialisation of emactuzumab.
July 8, 2024 at 12:10 PM. (Reuters) -Genentech, a unit of Roche Group, said on Monday it has re-launched its eye implant, Susvimo, in the United States, following the end of a voluntary recall ...